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Gouty arthritis is a relatively common 
diagnosis within the United States.  It is 
estimated that 9.2 million Americans 
suffer from gout (Golenbiewski & 
Keenan, 2019).  Gouty arthritis is also 
believed to be on the rise (Golenbiewski
& Keenan, 2019). This may correlate 
with the aging baby boomer generation 
since age is a risk factor.  The rise of 
conditions that increase the risk for 
gouty arthritis is another correlation 
(Harding, 2016).  These conditions 
include hypertension (HTN), type 2 
diabetes mellitus, and chronic kidney 
disease (Harding, 2016).  It is very 
probable that gouty arthritis will be 
encountered within the primary care 
setting.  Gouty arthritis is a condition 
that may be treated and managed in 
primary care by a family nurse 
practitioner (FNP).  FNPs should be 
knowledgeable of when to refer or 
consult with rheumatology specialists. 
The following is a fictitious case study 
that represents a scenario that could be 
encountered in primary practice:
• 48-year-old male presents with 
severe pain (“toe is on fire” 
description) in his right big toe, 
which is accompanied by 
inflammation and erythema
• Denies any fever, chills, or trauma
• Current prescription regimen: 
simvastatin 40 mg daily for 
hyperlipidemia for 6 years and 
hydrochlorothiazide 25 mg daily 
for HTN for 5 years
• Other factors include consistent 
weight gain for the past 5 years; he 
is about 50 pounds overweight
• Social history includes drinking a 
six-pack of beer daily
The remainder of this presentation will 
provide the FNP with the knowledge and 
tools on how to address and treat such a 
case.
Conclusion 
Signs & Symptoms
• Common initial presentation is redness, swelling, and pain of the big 
toe (Golenbiewski & Keenan, 2019)
• Feet, ankle, hands, wrists, elbows may also be affected (Golenbiewski
& Keenan, 2019) 
• Associated symptoms: shiny skin, mild fever or chills, loss of appetite 
(Golenbiewski & Keenan, 2019) 
Gout is a metabolic disorder that results in painful, sometimes debilitating, 
arthritis (Harding, 2016).  The cause of this condition is a buildup of uric acid 
in the blood and synovial fluid (McCance & Huether, 2018).  It is associated 
with purine metabolism and kidney function. Purines and pyrimidines in the 
body become converted to uric acid (McCance & Huether, 2018).  One 
enzyme that plays a role in the breakdown of uric acid is xandine oxidase 
(Golenbiewski & Keenan, 2019).  Uric acid is then filtered in the blood and 
excreted in the urine.  Uric acid has a limited solubility and the threshold of 
uric acid is about 6.8 mg/dL (Ragab, Elshahly, & Barin, 2017).  Uric acid loses 
a proton at a pH of about 7.4 and then becomes a urate ion (Ragab et al., 
2017). The urate ion binds sodium and forms monosodium urate crystals 
(MSU) (McCance & Huether, 2018).  MSU crystals are then deposited around 
the joints (McCance & Huether, 2018).  MSU crystals that are in the joint 
cavity initiate the inflammatory process(Golenbiewski & Keenan, 2019). 
Leukocytes will migrate to the affected site to release inflammatory 
chemicals such as cytokines (Golenbiewski & Keenan, 2019). Acute attacks 
are generally self-limited as mast cells help end the inflammatory period by 
engulfing debris and crystals (Raga et al. 2017).
Hyperuricemia can occur if there is decreased or overproduction of uric acid.  
Renal failure, HTN, and diuretics can lead to decreased excretion of uric acid 
(Berkowitz, 2007).  Causes of overproduction of uric acid include an 
overconsumption of purines in meats and alcohol, increased cellular turnover 
(hemolytic anemias or malignancies), and hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) deficiency (Lesch-Nyhan syndrome) 
which is an inherited X-linked disorder (Berkowitz, 2007).  90% of cases are 
caused by renal underexcretion (Ragab, et al, 2017).
Underlying Pathophysiology
There are four stages to gouty arthritis: asymptomatic 
tissue deposition, acute flares, inter-critical segments 
(continued crystal deposition), and chronic gout 
(American College of Rheumatology [ACR], 2019).  Key 
points to these phases include:
• Asymptomatic hyperuricemia may be an incidental 
finding and does not necessarily warrant treatment 
for gout (Golenbiewski & Keenan, 2019)
• SUA levels may be normal during an acute attack 
and require obtaining a baseline after the attack 
resolves (Harding, 2016)
• In the inter-critical segment, crystals remain and 
may require ongoing treatment for hyperuricemia 
(Ragab et al., 2017). 
• Repeated acute flare ups lead to chronic gouty 
arthritis. This leads to tissue destruction and 
deformity caused by tophi which permanent 
deposits of urate crystals along the joints (Ragab et 
al., 2017).  
• Chronic gout leads to an increased risk for kidney 
stones composed of urate and urate nephropathy 
(Harding, 2016). Urate nephropathy is a buildup of 
crystals in the kidney interstitium and tubules 
leading to renal failure.
Significance of Underlying 
Pathophysiology
Implications for Nursing Care
• Diagnosis can only be confirmed by identifying MSU crystals within 
synovial fluid (Ragab et al., 2017)
• Normal SUA levels are 3.5-7.2 mg/dL (ACR, 2019)
• Target SUA is <6 mg/dL (ACR, 2019)
• Treatment is aimed at lowering urate levels and making dietary 
changes.  Management of acute flares are aimed at managing 
inflammation and restoring function (Golenbiewski & Keenan, 2019).
• Not all respond to ULT and have refractory gout
• Medications for Acute Gouty Arthritis (Hanier, Matheson, & Wilkes, 
2014)
o NSAIDs (first line of therapy) 
o Colchicine (no analgesic properties; should not be 
administered after 36 hours of onset)
o Corticosteroids (preferred for NSAIDs and colchicine 
contraindication)
o Do not initiate urate lowering therapy (ULT) during an 
acute attack
• Medications for Prevention of Chronic Gouty Arthritis (Hanier et al., 
2014) 
o Colchicine 
o Pegloticase
o Xanthine oxidase inhibitors: Allopurinol, febuxostat
• Dietary recommendations: reduction or avoidance of foods that can 
increase SUA (Golenbiewski & Keenan, 2019):
o Alcohol
o Meats (organ, red and/or processed)
o High fructose corn syrup
• Risk factors (ACR, 2019):
o Lifestyle and other factors:
 Diet
 Alcohol consumption
 Male
 Family history
o Health conditions:
 HTN
 Obesity
 Hyperthyroidism
 Renal insufficiency
 Hemolytic anemia
 Kelley-Seegmiller syndrome
 Lesch-Nyhan syndrome
o Medications:
 Diuretics
 Salicylate containing drugs
 Niacin
 Cyclosporine
 Levodopa
Revisit the Case Study
Case Study
Within the case study and the information provided, 
it would be reasonable for the FNP to suspect an 
acute gout attack.  His age, sex, location/description 
of pain, inflammation of the big toe, history of HTN, 
prescription of the diuretic HCTZ, increased weight, 
and alcohol use are all factors that influence the 
development of gout.  The acute attack should be 
managed with appropriate pharmacologic therapy.  
Changing the HCTZ to another option to manage 
HTN should be considered.  A referral to a 
rheumatologist is appropriate to identify MSU 
crystals within the joint and to determine the long-
term plan.  Patient education regarding diet, weight, 
and alcohol use will be vital to help prevent future 
attacks and joint damage.    
Though gout is well understood, it 
generally remains poorly managed.  
The keys reasons for this are poor 
diet, widespread use of diuretics, 
comorbidities such obesity and HTN 
(Mead, Arabindoo, & Smith, 2014).  
Studies show that less than half of 
patients on urate lowering therapy 
are compliant with medication (Mead 
et al., 2014).  To help combat this 
issue, providers can increase follow-
up appointments (Mead et al., 2014).  
Acute flares are aimed at managing 
inflammation and restoring function 
(Golenbiewski & Keenan, 2019). Once 
the acute attack subsides, treatment 
is aimed at lowering urate levels and 
making dietary changes.  If non-
compliance is not thought to be an 
issue and the patient is not 
responding to treatment, refractory 
gout may need to be considered and 
treated accordingly. Finally, it is 
important for the FNP to note that 
guidelines for treatment may change 
in the future.  Current ACR guidelines 
were published in 2012.  These 
guidelines are currently under review 
and updated recommendations can 
be expected in 2020 (ACR, 2019).
Figure 3: Credit: Harding, 2016
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Figure 2: By NickGorton - NickGorton, CC BY 2.5, 
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Figure 1: MSU crystals 
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